INTRODUCTION
Lung cancer is a leading non-AIDS-defining cancer (NADC) and is the most frequent cause of cancer deaths in HIV-infected persons [1] [2] [3] . This is largely related to higher smoking rates among HIV-infected persons, as well as due to independent, HIV-related increased lung cancer risk [4] . With improved HIV disease control, larger numbers of patients are surviving long enough to develop and die from lung cancer [4, 5, 6 && ]. Several key questions exist regarding lung cancer in the setting of HIV infection. The mechanisms driving increased lung cancer risk (beyond higher rates of smoking) in HIV-infected persons remain largely unclear and are an area of active investigation. In addition, prognosis of HIV-infected persons who develop lung cancer has been shown to be worse than uninfected persons in several studies, but it is not known if this is related to treatment disparities, lung cancer therapy intolerance, greater risk of treatment toxicity or competing risk from AIDS and non-AIDS-related morbidity. Last, lung cancer prevention and early detection, an area of major clinical interest in HIV-uninfected persons, is an emerging area of study for HIVinfected persons.
In this review, we will provide an update on the recent scientific literature regarding lung cancer in HIV-infected persons, with a focus on these key areas of ongoing uncertainty.
INCIDENCE OF LUNG CANCER IN HIV INFECTION
Lung cancer incidence has been consistently reported as greater in HIV-infected persons than uninfected persons [4, 7] . Recent estimates from the multicohort North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) suggest that lung cancer cumulative incidence rates in HIV-infected persons continue to rise, but that this increase may reflect decreasing rates of all-cause mortality among HIV-infected persons. This NA-ACCORD analysis showed, however, that the underlying hazard of lung cancer is decreasing, possibly because of population-wide changes in smoking behavior and improved immune control in HIVinfected persons [6 && ]. An overall decrease in the crude incidence of lung cancer in HIV-infected persons was noted in the Veterans Aging Cohort Study (VACS) in the late antiretroviral therapy (ART) era when compared with earlier ART-era periods, consistent with hazard observations from NA-ACCORD [8 & ].
LUNG CANCER RISK IN HIV-INFECTED PERSONS
Lung cancer is a unique NADC; unlike most other malignancies (e.g. anal cancer, hepatocellular carcinoma and lymphoma) with increased frequency in the setting of HIV, it has no known predisposing viral coinfection [9] . Although some of the excess in lung cancer risk in HIVþ persons is due to an increased prevalence of smoking [4, 10] , multiple studies have shown that independent factors specifically associated with HIV infection also contribute to this increased risk [4, 5, 11, 12] .
Traditional lung cancer risk factors: age, smoking and obstructive lung disease HIV-infected smokers appear to develop lung cancer at an earlier age than uninfected persons [7, 13] . Smoking continues to be a major risk factor for lung cancer in the HIV-infected population [14] , where smoking rates continue to exceed the general population [15, 16] . Although some early evidence suggested that HIV-infected persons may develop lung cancer with less smoking exposure [5] , it is still unclear whether smoking has greater impact on lung cancer risk in HIV-infected persons compared with uninfected persons.
Chronic obstructive pulmonary disease (COPD) is a risk factor for lung cancer, independent of smoking, in HIV-uninfected persons [17, 18] . HIVinfected persons appear to be at greater risk of developing COPD, possibly because of higher smoking rates [19] , increased lung inflammation due to dysfunctional or increased levels of pulmonary CD8 activity [20, 21] or deleterious effects of recurrent or chronic lung infections [22] [23] [24] . COPD also appears to be an independent lung cancer risk factor for HIVinfected persons [25] , but there are no published data regarding COPD severity and lung cancer risk in HIVþ persons. Further investigation regarding the role of COPD in the development of lung cancer in the setting of HIV is warranted to better understand the interplay of immunologic and inflammatory factors that may be responsible for the increased lung cancer risk in this population.
HIV-specific risk factors: immunosuppression, inflammation, viral oncogenesis and antiretrovirals
Immunosuppression as measured by low CD4 cell count measures has shown limited association with lung cancer incidence when investigated as a static exposure, a finding noted in early studies [4, 11] , as well as a recent analysis of lung cancer predictors that combined data from the Womens Interagency HIV Study (WIHS) and the Multicenter AIDS Cohort Study (MACS) [7] . When evaluated as a longitudinal exposure, however, low CD4 measures appear to have a more robust independent association with lung cancer [26, 27] . In one of the largest analyses of immunologic risk factors for NADCs, Hleyhel et al. [26] found that HIV-infected persons who did not recover their CD4 cell count to at least 500 cells/ mm 3 were at increased risk of lung cancer. Inflammation, both locally in the lung and systemically, has also been investigated as a contributor to the increased lung cancer risk in HIV infection. Lung infections have been proposed as an acute inflammatory insult potentially contributing to the development of lung cancer in HIV-infected persons [28] . In the recent WIHS/MACS study, preceding pneumonia (even lagged 5 years) was an independent predictor of lung cancer [7] . Chronic inflammation within the lung related to HIV may also play a role in lung cancer development. Various mechanisms have been linked to pulmonary chronic inflammation in HIV including CD8 infiltration and dysregulation [20, 21] , viral impairment of epithelial integrity [29] and lung microbiome KEY POINTS HIV-infected persons are at greater risk of lung cancer than uninfected persons.
High smoking rates in HIV-infected persons are the largest contributor to lung cancer risk, but emerging evidence also suggests that immunosuppression and inflammation may also contribute to risk.
In the ART-era, HIV-infected persons appear to continue to experience lung cancer treatment disparities compared with uninfected persons.
Early clinical trials of CT-based lung cancer screening have demonstrated safety in HIV-infected smokers.
alterations [30, 31] , although direct correlations between lung chronic inflammation and subsequent lung cancer risk have not been proven in HIV-infected persons. It has also been suggested that HIV and smoking may have synergistic effects promoting lung inflammation, but this has received limited evaluation to date, and has not been linked to lung cancer risk [32] . Systemic inflammation associated with HIV infection has also been implicated in cancer risk; proinflammatory cytokines have been found to be elevated prior to lung cancer diagnosis in HIV-infected persons [33] .
Direct viral oncogenesis has been proposed as a mechanism for lung cancer in HIV infection. The lung may serve as a compartment in which HIV activity may not reflect systemic viral suppression [34] . This theory is supported by recent work from Cribbs et al. [35] showing that 70% of a cohort of 23 HIV-infected nonsmokers with ART-mediated viral suppression had measurable proviral DNA in alveolar macrophages. There has been no clear evidence of direct HIV oncogenesis in the lungs, however; early studies suggested that HIV viral proteins may have some direct oncogenic activity (not specific to lung cancer) via viral proteins [36, 37] , but data from a mouse model of HIV failed to confirm direct lung tumorigenesis [38] .
There have been no notable associations between ART exposure and increased lung cancer risk. The international Strategic Timing of Antiretroviral Treatment (START) trial found a significant decrease in all-cancer risk with immediate ART initiation compared with delayed initiation and a trend toward a decrease in NADC risk (15% of NADCs in START were lung cancers) [39] . D:A:D study investigators evaluated ART and lung cancer risk and found no overall or drug class-specific increased risk associated with ART [40] . Bruyand et al. [41] hypothesized that P450 cytochrome inhibitors (such as protease inhibitors) might influence the metabolism of lung carcinogens thereby increasing lung cancer risk, but did not find an association within the French Hospital Database.
CLINICAL CHARACTERISTICS OF LUNG CANCER
ART-era lung cancer in HIV-infected persons appears to have similar presenting clinical characteristics when compared with uninfected persons. Distributions of cancer stage at presentation and histologic subtypes have been similar by HIV status in data from large cohort studies [4, 42, 43 & ]. There are limited published data regarding the prevalence of clinically relevant oncogenic mutations found in lung cancers from HIV-infected persons. A recent study described the largest cohort to date, finding 3.3% EGFR mutations and 29% KRAS mutations in a cohort of 63 HIV-infected lung cancer patients [44] . Although the investigators did not compare these rates with uninfected comparators, these rates do not appear to differ markedly from expected rates in uninfected persons.
LUNG CANCER TREATMENT AND PROGNOSIS
The effects of HIV infection on lung cancer treatment tolerability, toxicity and effectiveness are not well known. Patients with serious comorbid conditions such as HIV are substantially underrepresented in clinical trials of cancer therapies [45] [46] [47] , and no prospective data have been published regarding lung cancer treatment in HIV-infected patients. Several small series and cohorts have reported treatment effectiveness estimates and complication rates for lung cancer therapies in HIVinfected patients. Surgical resection is the standard-of-care for early stage lung cancer, and a large ART-era analysis from the Veterans Affairs Health System found that HIV-infected patients may continue to experience more frequent surgical complications than uninfected patients [48 & ], although results specific to lung cancer surgery were limited. A comparative study evaluating lung cancer surgical outcomes in a cohort of 22 HIV-infected patients compared with uninfected comparators demonstrated more frequent surgical complications and poorer postsurgical survival [25] . Adjuvant therapies may also be associated with greater harms in HIVinfected patients; lung cancer chemotherapy outcomes were evaluated in a French cohort (n ¼ 56), and treatment was associated with a substantial number of deaths (12%) [49] . An Italian study described lung cancer treatments in their HIVinfected patients (n ¼ 68) and found an expected amount of major complications but commented that HIV-infected patients received fewer cycles of chemotherapy than indicated [50] .
These factors may have led to lung cancer treatment disparities in HIV-infected lung cancer patients compared with uninfected patients. Lung cancer treatment was often withheld in the pre-ART era because of poor overall prognosis [50] , and several large recent analyses have suggested that treatment disparities persist during the ART-era (Table 1) [43 & ,51-54] . In a cohort of patients at Kaiser Permanente California diagnosed with cancer from 1996 to 2011, those who were HIV infected were less likely to receive treatment for lung cancer than HIV-uninfected patients (64 vs. 76%, respectively); for unclear reasons, this disparity was not observed for any other NADCs. In the same study, only 16% of HIV-infected patients with lung cancer underwent surgery compared with 28% of HIV uninfected [43 & ]. A study of patients diagnosed with cancer from 1995 to 2009 found that 60.3% of those with both lung cancer and HIV received treatment for lung cancer compared with 77.5% of those with lung cancer who were uninfected [54] . Similar disparities were found in other population-based cohorts of HIV-infected and HIV-uninfected lung cancer cases [51, 52] . The cause of these treatment disparities remains unclear; they may be in part related to sociodemographic factors [51] , perception of greater risk or diminished benefits associated with treatment because of perceived underlying life expectancy, or a lack of specific guidance regarding lung cancer treatment in the setting of HIV.
The effect of HIV infection on lung cancerspecific prognosis has not been fully determined. Single and multicenter retrospective studies of lung cancer survival in the late ART-era have demonstrated a limited effect of HIV on outcomes. In contrast, population-based studies of lung cancer outcomes in HIV-infected persons have generally shown poorer cancer-specific survival associated with HIV infection (Table 2) 
LUNG CANCER PREVENTION AND EARLY DETECTION

Smoking cessation
Smoking cessation is the most effective method to prevent lung cancer in HIV-infected persons. Most published studies of lung cancer in HIV-infected persons have shown nearly 100% smoking rates [49, [59] [60] [61] . In addition, HIV-infected persons lose more life-years from smoking than HIV infection. In a Danish study, the median loss of life due to smoking in HIV-infected individuals was 12 years, as opposed to 5.1 years lost due to HIV in nonsmokers, reinforcing the public health importance of smoking cessation in this population [62] .
Behavioral and pharmacologic smoking cessation interventions have demonstrated efficacy in HIV-infected smokers. Several programmes in HIV-infected smokers have shown that when CI, confidence interval; NADC, non-AIDS-defining cancer; OR, odds ratio.
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self-efficacy is increased, chances of smoking cessation are improved [63] [64] [65] . In a recent metaanalysis of randomized controlled trials evaluating behavioral interventions for tobacco use in HIVinfected smokers, these interventions, particularly those with eight or more sessions, had a modest but significant effect on smoking cessation [66 & ]. Pharmacologic agents that have shown smoking cessation efficacy in the general population, including varencycline, bupropion and nicotine replacement therapy, have also been evaluated in HIVinfected smokers as part of smoking cessation programmes with evidence of safety and efficacy [63, [67] [68] [69] .
Lung cancer early detection with computed tomography
In 2011, the randomized National Lung Screening trial (NLST) demonstrated a significant all-cause mortality reduction of 6.7% and a lung cancer mortality reduction of 20% with three annual low-dose chest tomography (CT) examinations vs. simple chest radiography in high-risk individuals from the general population [70] . Since the publication of NLST results, several studies have attempted to clarify the benefits, harms and optimal indications associated with lung cancer screening using low-dose chest CT in HIV-infected persons.
Initial studies of chest imaging in HIV-infected persons showed high rates of incidental lung abnormalities, possibly due to a higher prevalence of lung infections, suggesting potentially higher rates of false-positive lung cancer screening tests [71] . A prospective study of asymptomatic HIV-infected Veterans compared the prevalence of clinically significant pulmonary nodules on baseline chest CT with the NLST and found that only individuals with CD4 cell counts below 200 cells/mm 3 had more significant nodules than the first round of screening in the NLST [72] . Two lung cancer screening clinical trials using chest CT in HIV-infected smokers have been published to date [73,74 && ]. The first study was conducted in Baltimore between 2006 and 2013, and enrolled a cohort with significant smoking history (median 34 pack-years) but was younger than the NLST (median age 48) [73] . Baseline screen positivity (a general measure of harms associated with screening, as most positive screens are false-positives) was broadly similar to NLST (14%). During 678 personyears of follow-up, only one lung cancer was found on an incident screening, although adherence to the study protocol was low.
The second lung cancer screening trial was a French National Agency of AIDS Research (ANRS) sponsored study [ 3 . In contrast to the Baltimore cohort, 10 lung cancers were diagnosed, of which nine were screen detected (60% were early stage cancers). Most individuals with lung cancer were younger than 55 years old, and would not have been screened according to the NLST criteria. The number of individuals needed to detect one lung cancer in this study was 49, which compares favorably with estimates in the general population [75] . Baseline rates of screen positivity were also broadly similar to NLST (21%) with low rates of diagnostic procedures performed.
It is not known if HIV-infected smokers will benefit from lung cancer screening at younger ages; this should be further assessed. Lung cancer riskprediction models including traditional and emerging immunologic risk factors in HIV-infected populations are also needed to focus screening efforts.
CONCLUSION
Lung cancer is a major source of morbidity and mortality for HIV-infected persons. The increased risk of lung cancer in HIV-infected persons is related to high rates of smoking and may also be associated with HIV-specific causes including immunodeficiency and inflammatory processes. Lung cancer outcomes for HIV-infected persons have lagged uninfected persons during the ART-era, and cancer treatment disparities contribute to decreased survival. Smoking cessation and lung cancer screening with chest CT scanning have emerging data supporting clinical implementation for appropriate groups of HIV-infected smokers. Future research should further address lung cancer risk in this population as well as identify and optimize effective prevention and treatment methods.
